Three former Hanmi Group executives filed a complaint with Seoul Yongsan Police Station on September 11 accusing Hanyang Precision Chairman Shin Dong-kuk and his eldest son, Shin Yu-seob, of embezzlement and breach of trust under the Act on the Aggravated Punishment of Specific Economic Crimes. The allegations concern approximately 467.3 billion won withdrawn through short-term loans between 2014 and 2023, another 44.4 billion won in loans in 2024 and 2025, a 113 billion won interim dividend paid in 2020, and about 49.6 billion won in transactions with affiliate H&D since 2021. Shin’s camp denies wrongdoing, saying the loans were repaid with statutory interest and recognized as normal in audits and tax investigations, while the dividend and H&D arrangement complied with applicable law and served a cost-saving business purpose. His representatives said they plan to consider counter-complaints for false accusation and defamation. The case follows Shin’s rapid expansion of his Hanmi Science stake to 28.15%, giving him and Hanyang Precision a combined 35.1%, amid a broader dispute over control of Hanmi Pharmaceutical Group.